Iterum Therapeutics (ITRM) Expected to Announce Quarterly Earnings on Thursday

Iterum Therapeutics (NASDAQ:ITRM) will likely be announcing its Q3 2025 results before the market opens on Thursday, November 13th. Analysts expect the company to announce earnings of ($0.13) per share for the quarter. Investors may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 13, 2025 at 8:30 AM ET.

Iterum Therapeutics (NASDAQ:ITRM) last announced its earnings results on Tuesday, August 5th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.03).

Iterum Therapeutics Stock Performance

Shares of ITRM stock opened at $0.62 on Thursday. The company has a market capitalization of $29.61 million, a price-to-earnings ratio of -0.72 and a beta of 3.09. The company has a 50-day simple moving average of $0.69 and a 200 day simple moving average of $0.85. Iterum Therapeutics has a 52 week low of $0.61 and a 52 week high of $3.02.

Wall Street Analyst Weigh In

Several analysts recently commented on ITRM shares. Wall Street Zen raised shares of Iterum Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Iterum Therapeutics in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $9.00.

Institutional Trading of Iterum Therapeutics

An institutional investor recently bought a new position in Iterum Therapeutics stock. Jane Street Group LLC acquired a new stake in Iterum Therapeutics PLC (NASDAQ:ITRM) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 92,943 shares of the company’s stock, valued at approximately $92,000. Jane Street Group LLC owned 0.21% of Iterum Therapeutics as of its most recent SEC filing. 9.21% of the stock is owned by institutional investors and hedge funds.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.